Upregulation of miR-21 in cisplatin resistant ovarian cancer via JNK-1/c-Jun pathway.

ABSTRACT: Cisplatin has been the most accepted drug for the treatment of ovarian cancer for almost 40 years. Although the majority of patients with ovarian cancer respond to front-line platinum combination chemotherapy, many patients will develop cisplatin-resistance disease, which is extremely rapid and fatal. Although various mechanisms of cisplatin resistance have been postulated, the key molecules involved in such resistance have not been identified. MiRNAs are endogenously expressed small non-coding RNAs, which are evolutionarily conserved and function as post-transcriptional regulators of gene expression. Dysregulation of miRNAs have been associated with cancer initiation, progression and drug resistance. The oncogenic miRNA-21, one of the best-studied miRNAs, is upregulated in almost all huma

SUBMITTER: Echevarria-Vargas IM 

PROVIDER: S-EPMC4035252 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature